



**SPANDIDOS
PUBLICATIONS**



**WORLD
ACADEMY
OF SCIENCES**

**24th WORLD CONGRESS ON ADVANCES IN ONCOLOGY
& 24th INTERNATIONAL SYMPOSIUM ON
MOLECULAR MEDICINE**

**OCTOBER 10-12, 2019
MYSTRAS, SPARTA, GREECE**



PROGRAM

Organized by the *International Journal of Oncology*,
Oncology Reports, *International Journal of Molecular Medicine*,
Molecular Medicine Reports, *Experimental and Therapeutic Medicine*,
Oncology Letters, *Molecular and Clinical Oncology*, *Biomedical Reports*
and *World Academy of Sciences Journal*

Welcome to Greece

Dear Colleagues,

On behalf of Spandidos Publications, it is my great pleasure to welcome you to Sparta for the 24th World Congress on Advances in Oncology and the 24th International Symposium on Molecular Medicine. This conference will allow the communication of the latest advances in the fields of oncology and molecular medicine by internationally renowned scientists. It will further facilitate the active collaboration between different research groups worldwide.

We are proud to report that the past year has built on the success of previous years for Spandidos Publications as we continue to grow, with record numbers of papers published in our nine journals. The newly released Impact Factors (2018 Journal Citation Reports® Edition) revealed further increases for several of our journals, indicating that the papers we publish are continuing to be more highly read and cited.

The scientific program for 2019 comprises lectures, short oral presentations and poster presentations, the best of which will be recognized with Certificates of Achievement at our traditional, end of Congress Award Dinner to be held on Saturday the 12th of October. In addition, we have organized six workshops. The first, pre-congress workshop, entitled 'SNP genotyping and rare mutation detection in cancer with molecular methods', is co-organized with TATAA Biocenter, Sweden, and will take place on the 8th and 9th of October. This workshop, which is the fifth in a series of annual pre-congress workshops, will focus on methods for nucleic acid analysis in cancer covering SNP genotyping, rare mutation analysis, methylation, copy number analysis, gene expression analysis, splice variants, microRNA and exosome analysis. Second, third and fourth of the workshops, entitled 'Workshop on Tumor Immunology, Microenvironment and Therapy', 'Workshop on Polyamines' and 'Workshop on Inflammation: The Cornerstone of Chronic Disease' will take place on the 11th of October and the fifth and sixth, entitled '5th Workshop on Paediatric Virology' and 'Workshop on Immuno-Dermatology/Oncology: Updates in Skin Cancer Therapies', on the 12th of October.

In addition, while you are here in Sparta, we hope that you will be able to explore some of the cultural and historic landmarks of Greece. This year, our Congress tours will include excursions to Monemvasia and Mani-Diros Caves. Monemvasia or the 'Gibraltar of the East' as it is also known, is a castle-town with a 15 centuries-old history, where you can enjoy a fantastic trip into a labyrinth of old paths winding till the hilltop, spectacular churches and gorgeous remains of fortifications. Mani-Diros Caves, one of the most beautiful lake caves in the world, is a large underground network of caves full of impressively shaped rock formations. The combination of colors, the wild beauty of the scenery and the turquoise waters of the bay will make this experience unforgettable. This could be an excellent opportunity to reunite with old acquaintances and make new ones, whilst exploring the magnificent natural environment and historical monuments.

We thank you for contributing to the success of this Congress and wish you a very pleasant stay in Greece.

Demetrios A. Spandidos

GENERAL INFORMATION

CONGRESS VENUE

Mystras Grand Palace Resort, Sparta, Greece

SECRETARIAT

The secretariat and the Registration Office:

Wednesday	9 October	14.30 - 19.00
Thursday	10 October	08.00 - 13.00 and 17.00 - 18.30
Friday	11 October	08.00 - 13.00 and 17.00 - 18.30
Saturday	12 October	08.00 - 13.00 and 17.00 - 18.30

REGISTRATION FEE

Active participant	Euro 500
Accompanying person	Euro 250

The registration fee includes:

Active participant:

- Admittance to scientific sessions
- Congress kit
- Welcome dinner
- Greek dinner & dancing
- Award dinner

Accompanying person:

- Welcome dinner
- Greek dinner & dancing
- Award dinner

BADGES

The name badges are required for admission to scientific sessions and social events

LUNCHEON

Luncheon facility is available at Mystras Grand Palace Resort for all registered persons

COFFEE BREAKS

Mid-morning and afternoon between sessions

SOCIAL PROGRAM

WELCOME DINNER

Thursday 10 October, 2019 at 20:00 hours

GREEK DINNER & DANCING

Friday 11 October, 2019 at 20:00 hours

AWARD DINNER

Saturday 12 October, 2019 at 20:00 hours

Check-out for accommodation, and registration fees at the Congress Reception.
(at the hotel reception, only for personal extras)

Scientific Program

BIOCHEMISTRY/MOLECULAR ONCOLOGY

Room A, 09:00-11:00
Thursday, October 10

Chair Persons: P.E. Nielsen, M. Kubista

- 131. Precision antisense antibiotics against multidrug-resistant Gram-negative bacteria. **P.E. Nielsen** (Copenhagen, Denmark) (30')
- 135. Two-tailed PCR and other ultrasensitive methods for the measurement of molecular cancer biomarkers. **M. Kubista**, P. Androvic, L. Valihrach, A. Herdean, A. Bergman, R. Sjöback (Gothenburg, Sweden; Vestec, Czech Republic) (30')
- 317. Role of RNA-binding proteins in the link between diabetes and cancer. B.S. Minch, K.M. Ponla, **J. Kim** (La Mirada, CA, USA) (30')
- 323. Interplay between oncogenes and non-coding RNAs in subtypes of non-Hodgkin B-cell lymphomas. **G. Malpeli**, S Barbi, C.M. Croce, C. Visco, A. Scarpa, A. Zamò (Verona; Turin, Italy; Columbus, OH, USA) (30')

SIGNAL TRANSDUCTION

Room A, 11:30-13:00
Thursday, October 10

Chair Persons: A.P. Fields, M.R. Berger, C. Mondello

- 168. Protein kinase C α and Wnt/ β -catenin signaling: Alternative pathways to *Kras/Trp53*-driven lung adenocarcinoma. N. Yin, Y. Liu, A. Khor, X. Wang, E.A. Thompson, M. Leitges, V. Justilien, C. Weems, N.R. Murray, **A.P. Fields** (Jacksonville, FL, USA; St. John's, Canada) (30')
- 121. The alkylphosphocholine erufosine is a multifaceted antineoplastic agent for its anticancer activities are based on interference with multiple signaling pathways. **M.R. Berger** (Heidelberg, Germany) (30')
- 128. Glutamine and asparagine cross-talk in cancer cells. I. Chiodi, D. Berardi, C. Perini, G. Casali, **C. Mondello** (Pavia, Italy) (30')

LUNCH AT MYSTRAS GRAND PALACE RESORT

13:00-15:00

CANCER THERAPEUTICS

Room A, 15:30-17:00

Thursday, October 10

Chair Persons: A. Bikfalvi, C. Parés Santilari, W. Brenner

228. New insights into tumor invasion and vascularization. **A. Bikfalvi** (Talence, France) (25')
232. The implication of exosomal miRNAs in the development of cancer represents the cornerstone of onco-regulation by Bio Immune(G)ene Medicine [BI(G)MED]. **C. Parés Santilari** (Barcelona, Spain) (25')
106. Inhibition of p38 in breast cancer is a questionable strategy. A. Breitbach, S. Gebhard, A. Hasenburg, **W. Brenner** (Mainz, Germany) (20')
312. The phenanthridine PJ34 exclusively eradicates human cancer cells. A. Castiel, L. Visochek, T. Golan, S. Izraeli, T. Peretz, **M. Cohen-Armon** (Ramat Gan; Jerusalem; Tel-Aviv, Israel) (20')

microRNAs

Room A, 17:30-19:00

Thursday, October 10

Chair Persons: R. Gambari, A. Finotti, W.-O. Lui

169. Targeting microRNAs in cystic fibrosis (CF). **R. Gambari** (Ferrara, Italy) (30')
175. Identification of dysregulated miRNAs in liquid biopsies from colorectal cancer (CRC) patients: Impact on personalized miRNA therapeutics. **A. Finotti**, R. Gambari (Ferrara, Italy) (30')
129. Merkel cell polyomavirus oncoproteins induce microRNAs that suppress multiple key genes in autophagy. S. Kumar, H. Xie, H. Shi, J. Gao, C.C. Juhlin, V. Björnhagen, A. Höög, L. Lee, C. Larsson, **W.-O. Lui** (Stockholm; Linköping, Sweden; Tianjin, P.R. China) (30')

Room A, 19:15

Thursday, October 10

Professor Apostolos Pierris: THE SPARTAN MIRACLE AND WORLD HISTORY

WELCOME DINNER

AT MYSTRAS GRAND PALACE RESORT

Room A, 20:00-23:00

Thursday, October 10

IMMUNOLOGY/MOLECULAR ONCOLOGY/HEMATOLOGY

Room B, 09:00-11:00

Thursday, October 10

Chair Persons: A. Vral, A.S. Tsiftoglou

120. Assessment of *in vitro* radiosensitivity in primary immune deficiency patients. **A. Vral**, A. Baeyens, K. Claes, C. Bonroy, V. Bordon, E. Beyls, E. Duthoo, L. Backers, S. Vermeulen, F. Haerynck (Ghent, Belgium) (20')
132. Human acute myeloid leukemia (AML): Leukemia stem cell (LSC) concept, molecular landscape and multilevel targeting. **A.S. Tsiftoglou**, S.A. Tsiftoglou (Thessaloniki, Greece) (20')
272. Microparticles released by myeloma plasma cells enhance thrombin generation in the microenvironment: A modelization *in vitro* study. **L. Papageorgiou**, P. Van Dreden, M. Dimopoulos, M. Mohty, G. Gerotziakas (Paris; Gennevilliers, France; Athens, Greece) (20')
223. IL-12 regulates the expansion of effector-like NK cells induced by IL-15/18 and alters their phenotypes and functions. N. Oka, T. Markova, M. Pencheva, W. Li, K. Yamanishi, H. Yamanishi, **H. Okamura** (Nishinomiya; Osaka, Japan; Sofia, Bulgaria) (20')
311. Tumor biology and cancer health disparity: Gene expression, cytokine secretion, and tumor immunology. **J. Paredes**, P. Ji, J. Garai, M. Spagnardi, X. Wang, E. Li, J. Zabaleta, L. Martello, J. Williams (Brooklyn, NY; Stony Brook, NY; New Orleans, LA; Tampa, FL, USA) (20')
102. Effective antitumor immunity against murine gliomas using dendritic cells transduced with hTERTC27 recombinant adenovirus. **H. Gong**, L. He, Y. Peng (Foshan; Guangzhou, P.R. China) (20')

CLINICAL ONCOLOGY/MOLECULAR ONCOLOGY

Room B, 11:30-13:15

Thursday, October 10

Chair Persons: F. Timeus, X.-F. Sun

149. Reduction of CFU-GM and circulating hematopoietic progenitors in a subgroup of children with chronic autoimmune neutropenia associated with severe infections and delayed recovery. **F. Timeus**, N. Crescenzo, L. Foglia, A. Doria, M.G. Stillitano, S. Vallerio, U. Ramenghi, P. Saracco (Turin, Italy) (15')
127. RhoB in relation to radiotherapy in colorectal cancer. N. Liu, W. Cui, X. Jiang, Z. Zhang, S. Gnosa, Z. Ali, L. Jensen, J.-I. Jönsson, S. Blockhuys, E.W.-F. Lam, Z. Zhao, J. Ping, N. Xie, M. Kopsida, X. Wang, **X.-F. Sun** (Linköping, Sweden; Xi'an; Shijiazhuang, P.R. China; London, UK) (15')
226. Hepatocellular carcinoma and resveratrol. **P. Slodnik**, C. Zeller (Ruti, Switzerland) (15')
146. Changes in normal brain ECM upon anti-glioblastoma chemotherapy are associated with experimental tumour growth *in vivo*. **M.A. Kolpakova**, A.Y. Tsidulko, O.B. Shevelev, A.S. Dotsenko, A.V. Suhovskih, E.L. Zavjalov, E.V. Grigorieva (Novosibirsk, Russia) (15')
289. MicroRNA biomarkers in sleep apnea. **H. Rezackova**, K. Houfkova, D. Slouka, J. Windrichova, M. Pesta, R. Kucera, O. Topolcan (Pilsen; Prague, Czech Republic) (15')
324. Autoantibody biomarkers differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. **M.O. Mowoe**, M. Bernon, K. Gandhi, S. Burmeister, H. Ali, M. Kahn, C. Kloppers, E. Jonas, J. Blackburn (Cape Town, South Africa) (15')
279. Prognostic value of contrast-enhanced MRI texture in the primary central nervous system lymphoma. **W. Guo**, C. Chen, X. Ma (Chengdu, P.R. China) (15')

METASTASIS/PROGRESSION

Room B, 15:30-17:00
Thursday, October 10

Chair Persons: M. Acevedo-Duncan, G. Perletti, L. Salerno

101. PKC- ι and PKC- ζ are heavily responsible for upregulating epithelial-mesenchymal transition (EMT) and activating Vimentin to facilitate cellular motility in prostate cancer cell lines. W.S. Ratnayake, C. Apostolatos, S. Breedy, R. Hill, C. Dennison, **M. Acevedo-Duncan** (Tampa, FL, USA) (25')
305. Evaluation of chronic prostatitis as possible a risk factor for prostate cancer. **G. Perletti**, E. Monti, V. Magri (Busto Arsizio; Milan, Italy) (25')
273. Inhibition of heme oxygenase-1 to improve cancer therapy. **L. Salerno**, S. Intagliata (Catania, Italy) (25')
274. Naloxone counteracts the promoting tumor growth effects induced by morphine in an animal model of triple negative breast cancer. **S. Bimonte**, A. Barbieri, M. Cascella, D. Rea, A. Luciano, G. Palma, A. Cuomo, C. Arra (Naples, Italy) (15')

APOPTOSIS/MOLECULAR ONCOLOGY

Room B, 17:30-19:00
Thursday, October 10

Chair Persons: H.M. Said, H. Zaid

256. TGF- β 1 pathway de-regulation in hypertrophic scar fibroblast cells - *in vitro*. **H.M. Said** (Izmir, Turkey) (20')
130. *H. triquetrifolium* potential anticancer activity: Apoptosis induction and cell cycle arrest of a colon cancer cell line and chemical analysis. **H. Zaid**, H. Mahajna, S. Kadan (Baq El Gharbia; Jerusalem, Israel; Jenin, Palestine) (15')
308. *Betula etnensis* Raf. (Betulaceae) extract induces HO-1 expression and ferroptotic cell death in human colon cancer cells. **G.A. Malfa**, B. Tomasello, R. Acquaviva, C. Genovese, A. La Mantia, F.P. Cammarata, M. Ragusa, M. Renis, C. Di Giacomo (Catania; Cefalù; Catanzaro, Italy) (15')
276. ETV7 as novel mediator of chemoresistance in breast cancer. L. Pezzè, F. Alessandrini, E.M. Meskyte, S. Pontalti, K. Badowska, D. Menendez, M.A. Resnick, **Y. Ciribilli** (Trento, Italy; Durham, NC, USA) (15')
290. Integrated analysis highlights multiple long non-coding RNAs reveal the potential roles in progression of human esophageal squamous cell carcinoma. **C.-Y. Li**, W.-W. Zhang, J.-L. Xiang, X.-H. Wang, J.-L. Wang, J. Li (Lanzhou; Wuwei, P.R. China) (10')
275. Securin: A novel marker and regulator of cancer stem cells in ovarian cancer. S. Parte, I. Virant-Klun, M. Patankar, S.K. Batra, A. Straughn, **S.S. Kakar** (Louisville, KY; Omaha, NE; Madison, WI, USA; Ljubljana, Slovenia) (15')

MOLECULAR MEDICINE/MOLECULAR ONCOLOGY

Room C, 09:00-11:00

Thursday, October 10

Chair Persons: Y. Zhang, J. Petrak, M. Pennisi

150. Comparison of the anti-atopic dermatitis effect of DHMEQ and tacrolimus ointments in a mouse model without stratum corneum. H. He, X. Gao, X. Wang, X. Li, X. Jiang, Z. Xie, J. Ma, K. Umezawa, **Y. Zhang** (Shenyang; Shenzhen, P.R. China; Nagakute, Japan) (20')
224. Membrane protein inventory of human pheochromocytoma and paraganglioma. O. Vit, K. Pacak, **J. Petrak** (Prague, Czech Republic; Bethesda, MD, USA) (20')
313. Elucidation of the catalytic cycle of type II DNA topoisomerase using a structural and molecular biological approach. I. Laponogov, X. Pan, D.A. Veselkov, I.M.T. Crevel, J. Selvarajah, A. Branstrom, R. Cirz, H.E. Moser, G. Skamrova, T. Umrekar, L.M. Fisher, **M.R. Sanderson** (London, UK; South Plainfield, NJ; San Francisco, CA; Emeryville, CA, USA) (20')
188. Modulation of the tumor microenvironment by liposomal prednisolone enhances the antitumor activity of liposomal doxorubicin in an *in vivo* model of murine melanoma. **E. Licarete**, D.-M. Drotar, I. Stejerean, L. Patras, V.-F. Rauca, L. Luput, A. Sesarman, M. Banciu (Cluj-Napoca, Romania) (20')
189. Novel therapies based on long-circulating liposomal simvastatin in colorectal cancer. **L. Luput**, E. Licarete, A. Sesarman, V.F. Rauca, L. Patras, A. Porfire, D. Muntean, M. Achim, I. Tomuta, L. Vlase, M. Banciu (Cluj-Napoca, Romania) (20')
220. Combination therapy of the liposome-encapsulated agents Simvastatin and DMXAA affects major mechanisms of murine melanoma development and progression. **V.-F. Rauca**, L. Patras, L. Luput, A. Sesarman, E. Licarete, V. Toma, A.C. Mot, M. Banciu (Cluj-Napoca, Romania) (20')

MOLECULAR ONCOLOGY/CLINICAL ONCOLOGY

Room C, 11:30-13:30

Thursday, October 10

Chair Persons: A.A. Alaiya, M. Alhosin, K.-C. Choi

117. Plasma proteomics biomarkers for redefining the HER-2/neu status in breast cancer patients regardless of their hormone receptors. **A.A. Alaiya**, Z. Shinwari, A. Tulbah, T. Twegieri (Riyadh, Saudi Arabia) (25')
257. Targeting of the epigenetic integrator UHRF1 in cancer cells by natural products. **M. Alhosin** (Jeddah, Saudi Arabia) (20')
318. Molecular mechanisms of pesticides as endocrine-disrupting chemicals on the progression and migration of estrogen receptor expressing breast cancers. R.-E. Go, **K.-C. Choi** (**Cheongju**, Republic of Korea) (15')
156. Thrombomodulin: Correlation with inflammatory and cardiac parameters in women with breast cancer and chemotherapy with doxorubicin. **R. Mendonça Cardoso Pestana**, R. Simões, L.M. Silva, H.H.M. Oliveira, A. De Paula Sabino, M.T. Alves, K.B. Gomes (Belo Horizonte, Brazil) (15')
219. Co-encapsulation of curcumin and doxorubicin in long circulating liposomes enhances the efficacy of colon cancer treatment. **A. Sesarman**, L. Tefas, B. Sylvester, E. Licarete, V. Rauca, L. Luput, L. Patras, S. Porav, M. Banciu, A. Porfire (Cluj-Napoca, Romania) (15')
325. Chromosomal studies on the Egyptian fresh water snail *Biomphalaria Alexandrina* by using transmission and scanning electron microscope. S. Ibrahim, **A.H. Mohamed**, S.M. El-Dafrawy (Giza, Egypt) (15')
292. Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: A retrospective study on Chinese patients and advances in hyperthermia. **M. He**, J. Sun, D. Zhao, H. He, B. Wang, L. Xu, Y. Shang, S. Ren, Y. Zhang, T. Wu (Dalian, P.R. China) (15')

IMMUNOLOGY/MOLECULAR ONCOLOGY

Room C, 15:30-17:00
Thursday, October 10

Chair Persons: M. Abdullah, A. Zaravinos

105. Immunogenetic influence on acute lymphoblastic leukaemia. **M. Abdullah**, L.J. Lee, S.Z. Idris, N. Hassan, S.H. Fong, C.K. Meng, J.S. Dhaliwal, H. Mohd Ibrahim, R. Osman (Kuala Lumpur, Malaysia) (30')
122. Immuno-profiling of the microenvironment of colorectal cancer. **A. Zaravinos**, C. Roufas, M. Nagara, B. De Lucas Moreno, M. Oblovatskaya, C. Efstathiades, C. Dimopoulos, G.D. Ayiomamitis (Nicosia, Cyprus) (15')
123. Correlation of the expression of immune checkpoint molecules with the tumor-infiltrating lymphocyte load, and survival in colorectal cancer patients. M. Kitsou, **A. Zaravinos** (Nicosia, Cyprus) (15')
283. Contrast-enhanced CT-based textural parameters as potential prognostic factors of survival for colorectal cancer patients receiving targeted therapy. **X. Ma**, J. Yang, T. Zhang (Chengdu, P.R. China) (10')
284. Discrimination of pituitary adenomas and craniopharyngioma on MRI: From image features to texture features. **H. Xu**, W. Guo, X. Ma (Chengdu, P.R. China) (10')
315. Prediction application of mRNA markers for colorectal polyps by membrane array. **B. Feng**, M. Feng, H. Shi (Shandong, P.R. China) (10')

MOLECULAR ONCOLOGY/PHARMACOLOGY

Room C, 17:30-19:00
Thursday, October 10

Chair Persons: T. Kondo, Y. Suzuki-Karasaki

104. Chemical screening-based discovery of a novel drug against glioblastoma-initiating cells. S. Echizenya, Y. Ishii, S. Kitazawa, T. Hatta, T. Natsume, S.-I. Watanabe, S. Hagiwara, **T. Kondo** (Hokkaido; Kanagawa; Tokyo, Japan) (25')
217. Mitochondrial network collapse is an essential process in cancer cell death induction by cold atmospheric plasma-activated liquids. **Y. Suzuki-Karasaki** (Nasushiobara, Japan) (20')
218. Air plasma-activated medium induces an iron-dependent ferroptosis-like cell death in human malignant tumor cells. **M. Suzuki-Karasaki**, A. Takashi, Y. Ochiai, M. Suzuki-Karasaki, Y. Yoshida, T. Ochai, Y. Suzuki-Karasaki (Tochigi; Yamanashi; Tokyo, Japan) (15')
157. Druggable kinases activated by disruptive TP53 mutations in solid tumors. Á. Ósz, Á. Nagy, **B. Győrffy** (Budapest, Hungary) (15')
267. OXA-48 and other carbapenemases as resistance determinants in *Klebsiella Pneumoniae* strains isolated from blood cultures: Molecular and phenotypic determination. M. Tompa, S.L. Pandrea, M.I. Ciontea, M. Grigorescu, R. Tompa, S.M. Pandrea, **L.M. Junie** (Cluj Napoca, Romania) (15')

EXPERIMENTAL THERAPEUTICS

Room A, 09:00-11:00
Friday, October 11

Chair Persons: S.N. Karagiannis, M.Z. Ratajczak

213. Antibody-mediated re-programming of macrophages against tumours: New insights for cancer immunotherapy. **S.N. Karagiannis** (London, UK) (30')
107. Cancer from the perspective of stem cells and misappropriated tissue regeneration mechanisms. **M.Z. Ratajczak**, J. Ratajczak (Louisville, KY, USA) (30')
281. Role of cathepsin B circular RNAs in tumor cells. M. Gnanamony, **C.S. Gondi** (Peoria, IL, USA) (20')
280. Expression of the EMT-associated transcription factor Slug/SNAI2 in epithelial colon cancer cells is accompanied by increased invasiveness and VEGF secretion but not by altered drug sensitivity. **K. Amilca**, A. Bouygues, S. Thouroude, L. Louadj, S. Chrstensen, M. Sabbah, J. Denis, A.K. Larsen (Paris, France) (20')
282. Autophagy dependence of small molecule angiokine inhibitors in colorectal cancer. **L. Louadj**, P. Mésange, M. Sabbah, A.K. Larsen (Paris, France) (20')

THERAPEUTICS/TUMOR MICROENVIRONMENT

Room A, 11:30-13:00
Friday, October 11

Chair Persons: R. Gupta, P.S. Rennie, T.W. Grunt

265. Milk-derived exosomes – A nano platform for delivery of small and large molecules. **R. Gupta**, F. Aqil, J. Jeyabalan, A.-H. Kyakulaga, A. Agrawal, N. Tyagi, R. Kandimalla, D.J. Schultz, W. Spencer, R. Munagala (Louisville, KY, USA) (30')
109. Development of small molecule Myc-Max inhibitors as potential therapeutics for prostate cancer. **P.S. Rennie**, N. Lallous, L.A. Carabet, A. Cherkasov (Vancouver, Canada) (30')
111. Hit one to eliminate all during cancer treatment: The crucial role of fatty acid synthase (FASN) in ovarian cancer (OC) growth. A. Slany, R. Wagner, G. Stübiger, M. Semkova, R. Colomer, M.L. López-Rodríguez, C. Gerner, **T.W. Grunt** (Vienna, Austria; Madrid, Spain) (30')

LUNCH AT MYSTRAS GRAND PALACE RESORT

13:00-15:00

EXPERIMENTAL THERAPEUTICS

Room A, 15:30-17:00

Friday, October 11

Chair Persons: A.K. Larsen, N.R. Murray, M. Danilenko

215. Influence of the mesenchymal phenotype on the response to VEGF-targeted agents in the treatment of colorectal cancer. **A.K. Larsen**, L. Louadj, S. Thouroude, A. De Gramont, B. Chibaudel, J.-P. Thiery, J. Denis, A. Bouygues (Paris; Levallois-Perret, France; Singapore) (30')
155. Protein kinase C δ promotes pancreatic tumorigenesis. K.S. Inman, M.L. Scotti Buzhardt, M. Leitges, M. Krishna, H.C. Crawford, A.P. Fields, **N.R. Murray** (Jacksonville, FL; Durham, NC; Charlotte, NC; Ann Arbor, MI, USA; Oslo, Norway) (30')
158. Vitamin D derivatives and their combinations with clinically relevant agents in the differentiation therapy of acute myeloid leukemia. H. Nujdat, A. Dawod, A. Trachtenberg, A. Kutner, G.P. Studzinski, **M. Danilenko** (Beer-Sheva, Israel; Warsaw, Poland; Newark, NJ, USA) (30')

MOLECULAR ONCOLOGY

Room A, 17:30-19:00

Friday, October 11

Chair Persons: C. Demonacos, M. Krstic-Demonacos

182. Endoplasmic reticulum stress in the evasion of immuno-surveillance and resistance to anticancer therapy of breast cancer cells. R. Al-Hammad, S. Khunchai, N. Tongmuang, T. Limjindaporn, P.-T. Yenchitsomanus, M. Krstic-Demonacos, **C. Demonacos** (Manchester; Salford, UK; Phitsanulok; Bangkok, Thailand) (30')
183. Bioinformatics and clinical practice: Predictive models in the stratification of cancer patients and the identification of novel therapies. K. Tian, E. Bakker, M. Hussain, A. Guazzelli, H. Alhebshi, P. Meysami, C. Demonacos, J.-M. Schwartz, L. Mutti, **M. Krstic-Demonacos** (Salford; Preston; Cardiff; Manchester, UK; Philadelphia, PA, USA) (30')
277. Determination of the effectiveness of serum cytokeratins as tumor markers for early stage breast cancer. **M. Karlikova**, O. Topolcan, A. Narsanska, R. Kucera, H. Rezackova, **V. Treska** (Pilsen, Czech Republic) (30')

Room A, 19:15

Friday, October 11

Professor Sir Salvador Moncada: ON NEED TO CONCENTRATE ON THE PREVENTION AND EARLY DETECTION OF CANCER

GREEK DINNER
AT MYSTRAS GRAND PALACE RESORT

Room A, 20:00-23:00

Friday, October 11

WORKSHOP ON TUMOR IMMUNOLOGY, MICROENVIRONMENT AND THERAPY

Organized by **L. Vannucci**

Room B, 09:00-11:00

Friday, October 11

Chair Persons: L. Vannucci, M. Kverka

115. Re-thinking the tumor microenvironment. **L. Vannucci**, P. Lukac, P. Tenti, F. Caja, D. Stakheev, O. Chernyavskiy, D. Vondrasek, L. Kubinova, L. Rajsiglova, T. Hudcovic, H. Kozakova, J. Dvorak, P. Sima, P. Vodicka, L. Vodickova, P. Makovicky, P. Makovicky, R. Sedlacek, M. Levy (Prague; Novy Hradek; Vestec, Czech Republic; Komarno, Slovak Republic) (30')
114. Immunomodulatory properties of dietary components, commensal microbiota and antibiotics. **M. Kverka**, K. Kostovcikova, Z. Jiraskova Zakostelska, S. Coufal, Z. Stehlikova, N. Galanova, A. Fajstova, T. Hudcovic, T. Hrcir, M. Kostovcik, H. Tlaskalova-Hogenova (Prague; Novy Hradek, Czech Republic) (25')
137. On the way to cytokine-antibody single-chain fusions for cancer immunotherapy. **J. Tomala**, S. Ludwig, H. Yang, M. Leff, J. Spangler, M. Kovar (Prague, Czech Republic; Baltimore, MD, USA) (25')
142. Immunobiological changes in human colorectal cancer and 3D cancer modelling *in vitro*. **P. Lukac**, P. Tenti, F. Caja, D. Stakheev, J. Svoboda, O. Chernyavskiy, D. Vondrasek, L. Rajsiglova, P. Makovicky, M. Levy, P. Makovicky, R. Sedlacek, L. Vannucci (Prague; Vestec, Czech Republic; Komarno, Slovak Republic) (20')
144. Lysyl oxidases and the formation of the early tumoral niche. **P. Tenti**, L. Rajsiglova, P. Lukac, L. Vannucci (Prague, Czech Republic) (20')

WORKSHOP ON TUMOR IMMUNOLOGY, MICROENVIRONMENT AND THERAPY

Organized by **L. Vannucci**

Room B, 11:30-13:00

Friday, October 11

Chair Persons: M. Kovar, M. Šírová

110. Ritonavir as a novel antitumor drug candidate. L. Sivak, V. Subr, L. Kostka, T. Etrych, B. Rihova, **M. Kovar** (Prague, Czech Republic) (25')
138. Polymer prodrugs for the treatment of experimental solid tumors and immunomodulation. **M. Šírová**, I. Malátová, K. Hrabánková, L. Sivák, B. Říhová, M. Studenovský, P. Chytil, T. Etrych (Prague, Czech Republic) (25')
139. Micellar polymer drug delivery systems for the treatment of chemoresistant tumors. **M. Kaňá**, A. Braunová, T. Etrych, J. Bouček, M. Šírová (Prague; Czech Republic) (20')
143. *In vitro* and *in vivo* evaluation of ferric and ferritin-based nanoparticles from the theranostic perspective. **L. Rajsiglova**, P. Lukac, P. Tenti, M. Babic, D. Jirak, P. Makovicky, R. Sedlacek, E. Falvo, P. Ceci, L. Vannucci (Prague; Vestec, Czech Republic; Rome, Italy) (20')

DIAGNOSTICS/BIOMARKERS/GENETICS

Room B, 15:30-17:00

Friday, October 11

Chair Persons: G.N. Goulielmos, E. Eliopoulos

134. Shaping the genetic profile of endometriosis through the correlation of gene polymorphisms with protein functionality. **G.N. Goulielmos**, E. Eliopoulos, M. Matalliotakis, C. Matalliotaki, D.A. Spandidos, M.I. Zervou (Heraklion; Athens; Thessaloniki, Greece) (15')
133. Genetics of autoimmune diseases: From gene to protein structure and function. **M.I. Zervou**, E. Eliopoulos, G.N. Goulielmos (Heraklion; Athens, Greece) (15')
161. Attempts to link exonic gene polymorphisms to disease-associated protein modified functionality: A structural biology approach. **E. Eliopoulos**, M.I. Zervou, G.N. Goulielmos, M. Matalliotakis, D. Vlachakis (Athens; Heraklion; Thessaloniki, Greece) (30')
159. Dark genome and its regulation by long non-coding RNAs. K. Pierouli, G.N. Goulielmos, E. Eliopoulos, **D. Vlachakis** (Athens; Heraklion, Greece) (15')
160. Genome-wide association studies (GWAS) in an effort to provide insight into the complex interplay of nuclear receptor transcriptional networks and the contribution to the maintenance of homeostasis: The role of the glucocorticoid receptor. T. Mitsis, G.P. Chrousos, E. Eliopoulos, **D. Vlachakis** (Athens, Greece) (15')

MOLECULAR MEDICINE

Room B, 17:30-19:00

Friday, October 11

Chair Persons: I. Panagopoulos, T. Vlaykova

269. Fusion genes in cancer: From cytogenetics to next generation sequencing. **I. Panagopoulos** (Oslo, Norway) (30')
140. MMP-9 serum levels and 2127G>T intron 4 polymorphism in patients with cutaneous melanoma. **T. Vlaykova**, T. Tacheva, E. Vachkova, D. Vlaykova, G. Beev, D. Dimov (Stara Zagora, Bulgaria) (20')
141. Serum 25-hydroxyvitamin D levels in patients with COPD. **D. Dimov**, T. Tacheva, Y. Zhelyazkova, E. Slavov, D. Vlaykova, T. Vlaykova (Stara Zagora, Bulgaria) (20')
136. ALDH1A1: The novel biomarker of pancreatic cancer stem cells. **H.-Q. Duong** (Hanoi, Vietnam) (20')

WORKSHOP ON POLYAMINES/MOLECULAR MEDICINE

Organized by E. Agostinelli

Room C, 09:00-11:00

Friday, October 11

Chair Persons: E. Agostinelli, T. Oka

231. Inhibition of EIF-5A prevents cardiac symptoms in complicated malaria through apoptosis. K. Heiss, A.-K. Mueller, R. Fimmers, J. Matthes, J.T. Njuguna, **A. Kaiser** (Essen; Heidelberg; Bonn; Köln, Germany; Kampala, Uganda) (30')
221. Spermine metabolite, hydrogen peroxide and aldehyde, induce the apoptosis of neuroblastoma cells associated with an increase in p53, Caspase-3 and miR-34a. **E. Agostinelli**, Y. Kanamori, A. Finotti, L. Di Magno, G. Canettieri, S. Ohkubo, F. Timeus, J. Gasparello, I. di Liegro, R. Gambari (Rome; Ferrara; Turin; Palermo, Italy) (30')
239. New compounds inhibiting trypanothione reductase: An attractive target to develop drugs against Human African Trypanosomiasis. **T. Battista**, L. Turcano, E. Torrente, A. Missineo, M. Andreini, S. Harper, A. Bresciani, A. Fiorillo, G. Colotti, A. Ilari (Rome, Italy) (30')
303. Products of spermine oxidation by bovine serum amine oxidase cause membrane permeabilization in hepatoma cell mitochondria: A new physiological mechanism for regulating cell death induction in tumor mitochondria. **A. Toninello**, S. Grancara, L. Dalla Via, A.N. Garcia-Argaez, S. Merali, C. Barrero, Y. Kanamori, E. Agostinelli (Padova; Rome, Italy; Philadelphia, PA, USA) (30')

MOLECULAR MEDICINE/ONCOLOGY

Room C, 11:30-13:25

Friday, October 11

Chair Persons: S. Merali, L. Dalla Via

307. Polyamine metabolism in the pathogenesis of non-alcoholic steatohepatitis. **C. Quinn**, M. Rico, C. Merali, S. Merali (Philadelphia, PA, USA) (30')
238. Cues to the development of T cell memory to improve cancer immunotherapies. R.E. Hesterberg, A. Elmarsafawi, **P.K. Epling-Burnette** (Tampa, FL, USA) (20')
304. KDM1A and SMOX: Dual inhibition of regulatory pathways for cancer metastasis. **S. Holshouser**, M. Dunworth, T. Murray Stewart, Y.K. Peterson, P. Burger, H.-H. Chen, R.A. Casero Jr, P.M. Woster (Charleston, SC; Baltimore, MD, USA) (25')
240. New agents to challenge drug resistance in cancer. M. Hyeraci, M.P. Rigobello, S. Samaritani, **L. Dalla Via** (Padova; Pisa, Italy) (20')
214. Polyamines as mediators of secondary metabolite production in filamentous fungi. G. Nuraeva, **A. Zhgun** (Moscow, Russia) (20')

WORKSHOP ON INFLAMMATION: THE CORNERSTONE OF CHRONIC DISEASE

Alteration of Cellular Microenvironment

Organized by S.S. Signorelli and M. Libra

Room C, 15:30-17:00

Friday, October 11

Chair Persons: L. Falzone, C. Fenga, M. Banciu

191. Impact of fecal microbiota transplantation on short chain fatty acid levels in feces of patients with inflammatory bowel diseases. **E. Zhgun**, Y. Kislun, A. Pavlenko, T. Kalachniuk, E. Ilina (Moscow, Russia) (15')
264. Gene-environment interactions and pesticide toxicity in exposed workers. **C. Fenga**, M. Teodoro, G. Briguglio, C. Costa (Messina, Italy) (15')
242. Identification of pro-inflammatory microRNAs as diagnostic and prognostic biomarkers for oral cancer. **L. Falzone**, S. Vivarelli, R. Salemi, S. Candido, M. Libra (Catania, Italy) (15')
236. Combined melanoma-targeted therapies to suppress tumor microenvironment cell-mediated processes. E. Licarete, V.F. Rauca, A. Sesarman, L. Luput, L. Patras, **M. Banciu** (Cluj-Napoca, Romania) (15')
247. Implication of the transcription factor YY1 in non-Hodgkin's lymphoma. **S. Vivarelli**, L. Falzone, S. Candido, M. Libra (Catania, Italy) (15')
244. Anti-proliferative effects of cell-free supernatants from *Lactobacillus rhamnosus* GG in cancer cells. **R. Salemi**, S. Candido, L. Falzone, S. Vivarelli, M. Santagati, M. Libra (Catania, Italy) (15')

WORKSHOP ON INFLAMMATION: THE CORNERSTONE OF CHRONIC DISEASE

Molecular Markers in Human Disease

Organized by S.S. Signorelli and M. Libra

Room C, 17:30-19:00

Friday, October 11

Chair Persons: S.S. Signorelli, S. Candido

245. Incidence of venous thromboembolism (VTE) in patients with multiple myeloma (MM): A monoinstitutional experience. **S.S. Signorelli** (Catania, Italy) (20')
241. Methylation profiling of genes involved in inflammation and immune response in melanoma. **S. Candido**, R. Salemi, L. Falzone, G. Gattuso, S. Vivarelli, M. Libra (Catania, Italy) (20')
246. Role of the transcription factor YY1 in colorectal cancer. **S. Vivarelli**, L. Falzone, S. Candido, M. Libra (Catania, Italy) (20')
243. Inverse microRNA expression patterns in glioblastoma multiforme and Alzheimer's disease. **L. Falzone**, M. Pennisi, S. Vivarelli, R. Salemi, S. Basile, S. Candido (Catania, Italy) (15')
263. Relationship between genetic polymorphisms and pesticide-induced oxidative damage in exposed workers. **M. Teodoro**, D. Caccamo, G. Briguglio, C. Costa, C. Fenga (Messina, Italy) (15')

MOLECULAR ONCOLOGY

Room A, 09:00-11:00

Saturday, October 12

Chair Persons: S. Savas, A. Semczuk, P. Vodička

103. The SWI/SNF complex subunit genes and their relation to patient survival times in human cancers. **S. Savas**, G. Skardasi, Y. Yu (St. John's, Canada) (30')
270. Expression of selected cytokeratins in neoplastic endometrium. D. Vasilevska, A. Semczuk-Sikora, D. Lewkowicz, M. Jóźwik, M. Bogusiewicz, **A. Semczuk** (Vilnius, Lithuania; Lublin; Bialystok, Poland) (30')
271. Chromosomal damage, relative telomere length and DNA repair in colorectal and breast carcinogenesis. **P. Vodička**, M. Kroupa, L. Vodičková, Z. Polívková, L. Mušák, M. Dušínská, S. Vodenková, S. Rachakonda, V. Vymetálková, A. Naccarati, R. Kumar, K. Hemminki (Prague; Pilsen, Czech Republic; Martin, Slovakia; Lillestroem, Norway; Turin, Italy; Heidelberg, Germany) (20')
287. Chemotherapeutic stress is accompanied by pro-invasive signaling in colorectal cancer models. **S. Thouroude**, P. Van Dreden, G.T. Gerotziafas, A.K. Larsen (Paris, France) (20')
288. Lithium chloride increases sensitivity to photon radiation treatment in primary mesenchymal colon cancer cells. F. Cammarota, A. Aversano, G. Ametrano, P. Delrio, P. Riccio, M. Turano, V. Valente, P. Izzo, G.M. Pierantoni, **M. De Rosa** (Naples, Italy) (20')

5th WORKSHOP ON PAEDIATRIC VIROLOGY

Organized by the **Paediatric Virology Study Group**

Room A, 11:30-13:00

Saturday, October 12

Chair Persons: B. Rath, S.B. Drysdale, G. Papaioannou

187. Understanding the burden of RSV and influenza infections in real-time: Partnering for enhanced digital surveillance of influenza-like disease and the effectiveness of antivirals and vaccines (PEDSIDEA). **B. Rath** (Berlin, Germany; Besancon, France; Nottingham, UK) (30')
186. Management of RSV infection in children: New advances and challenges. **S.B. Drysdale** (London, UK) (30')
202. High-flow warm humidified oxygen via nasal cannula and RSV-positive bronchiolitis among children admitted to PICU. **A. Papatheodoropoulou** (Athens, Greece) (15')
201. Imaging in children with RSV infection. **G. Papaioannou** (Athens, Greece) (15')

LUNCH AT MYSTRAS GRAND PALACE RESORT

13:00-15:00

5th WORKSHOP ON PAEDIATRIC VIROLOGY
Organized by the **Paediatric Virology Study Group**

Room A, 15:30-17:00
Saturday, October 12

Chair Persons: M. Theodoridou, I.N. Mamas, G.P. Chrousos

200. Prevention of RSV infections: An update on vaccines. **M. Theodoridou** (Athens Greece) (30')
254. The neonatal immune response to RSV infection: Advances in our understanding of viral and host cellular interactions.
E. Koutsounaki (Athens, Greece) (20')
255. Stress and viral infections. **G.P. Chrousos** (Athens, Greece) (40')

AWARD DINNER
AT MYSTRAS GRAND PALACE RESORT

Room A, 20:00-23:00
Saturday, October 12

WORKSHOP ON IMMUNO-DERMATOLOGY/ONCOLOGY:
UPDATES IN SKIN CANCER THERAPIES
Organized by D. Boda and M. Neagu

Room B, 09:00-11:00
Saturday, October 12

Chair Persons: M. Neagu, D. Boda

205. Immune biomarkers in skin cancer therapy. **M. Neagu**, C. Constantin, C. Caruntu, M. Surcel, S. Zurac (Bucharest, Romania) (20')
204. *In vivo* reflectance confocal microscopy for basal cell carcinoma diagnosis and subtyping. **D. Boda** (Bucharest, Romania) (20')
203. Role of neuroendocrine factors in skin cancer. **C. Caruntu**, D. Boda, A. Caruntu, S. Zurac, C. Constantin, M. Neagu (Bucharest, Romania) (20')
262. Neural plasticity in vascular cognitive impairment: Translational findings from transcranial magnetic stimulation. **M. Pennisi** (Catania, Italy) (20')
278. Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors. G. Scognamiglio, A. De Chiara, F. Fazioli, M. Gallo, L. Aversa, R. Camerlingo, R. Pili, **F. De Nigris** (Naples, Italy; Indianapolis, IN, USA) (15')
285. Epigenetic analysis of depression-like behavior in interleukin-18-deficient mice. **K. Yamanishi**, K. Mukai, T. Hashimoto, M. Miyauchi, K. Ikubo, N. Uwa, Y. Watanabe, C. Yamanishi, H. Okamura, H. Matsunaga (Nishinomiya; Hirakata, Japan) (15')
291. The prognostic value of 18F-FDG PET/CT radiomics features in patients with primary gastric diffuse large B-cell lymphoma. **H. Liang**, R. Zhou, X. Ma (Guanghan; Chengdu, P.R. China) (10')

CHALLENGES FOR AGING AND CHRONIC DISEASES BIO-MARKERS:
TELOMERASE AND TELOMERE LENGTH

Room B, 11:30-13:15
Saturday, October 12

Chair Persons: A.M. Tsatsakis, N. Drakoulis, D. Tsoukalas

260. Telomeres and telomerase biomarkers and advances in reproductive research. P. Fragkiadaki, C. Kalliora, E. Vasilopoulos, D. Tsoukalas, E. Vakonaki, E. Renieri, E. Sarandi, D.A. Spandidos, **A.M. Tsatsakis** (Heraklion; Athens, Greece; Philadelphia, PA, USA; Craiova, Romania) (20')
152. Pharmacogenetics and pharmacogenomics in precision pharmacotherapy. **N. Drakoulis** (Athens, Greece) (20')
237. Clinical application of telomere length measurements: A challenge for precision medicine. **D. Tsoukalas**, G. Tsilimidos, P. Fragkiadaki, A. Alegakis, E. Sarandi, E. Vakonaki, A. Tsatsakis (Athens; Heraklion, Greece; Craiova, Romania) (20')
216. Application of proteomics in target identification for personalized anticancer therapies. **G.M. Nitulescu** (Bucharest, Romania) (15')
259. Implications on telomeres length by chronic exposure to drugs of abuse and pesticides. **V. Karzi**, E. Vakonaki, M.N. Tzatzarakis, A.M. Tsatsakis (Heraklion, Greece) (10')
248. Telomere maintenance regulated by a cell cycle-controlled mechanism: From bench to clinic. **M. Thanasoula**, D. Tsoukalas, E. Sarandi, A. Docea, A.M. Buga, A. Tsatsakis (Athens; Heraklion, Greece; Craiova, Romania) (10')
249. Metabolomics application in precision medicine: Prediction and treatment of chronic diseases. **E. Sarandi**, D. Tsoukalas, G. Tsilimidos, D. Calina, A. Tsatsakis (Athens; Heraklion, Greece; Craiova, Romania) (10')

MOLECULAR ONCOLOGY

Room B, 15:30-17:00
Saturday, October 12

Chair Persons: C.R. Osses, F. Méndez-López

119. Role of miR-145-conjugated gold-nanoparticles as a potential adjuvant therapy for epithelial ovarian cancer. E. Salas, L. Lobos, F. Morales, M. Kogan, M. Garrido, M. Vega, **C.R. Osses** (Chile; Desarrollo, Czech Republic) (20')
185. Carcinogenesis: A systems biology approach. **F. Méndez-López** (San Nicolas, Mexico) (20')
167. Novel approaches to parvovirus B19 diagnostics in cancer patients. **A. Babenka**, M. Yermalovich, I. Anufrionak, V. Egorova, I. Lipnevich, N. Krylova, H. Grushevskaya (Minsk; Lesnoy, Belarus) (20')
233. Loss function of PITX1 contributes to a poor prognosis of gastric cancer patients by enhancing chemotherapy resistance to 5-fluorocytosine and cisplatin. **X. Shen**, F. Qiao, P. Gong, Z. Zhao, H. Fan (Nanjing, P.R. China) (15')
234. Methylation pattern of H3K9me3, H3K36me3 and H4K20me3 correlated with patient prognosis contributes to esophageal squamous cell carcinoma. **M. Zhou**, Y. Li, S. Lin, Y. Qian, Z. Zhao, H. Fan (Nanjing; Fuzhou, P.R. China) (15')

BREAST CANCER

Room B, 17:30-19:00
Saturday, October 12

Chair Persons: I. Barash, H.M. Romanska

118. De-regulated Stat5 activity during pregnancy represents a risk factor for latent breast cancer development: Studies on a transgenic mouse model. S. Laufer, A. Kosenko, T. Kisliouk, **I. Barash** (Bet-Dagan; Jerusalem, Israel) (20')
126. FGFR2-mediated signaling in luminal breast cancer: Implications for therapy and prognostication. **H.M. Romanska**, L. Turczyk, D. Piasecka, D. Czaplinska, K. Kitowska, R. Kordek, P. Potemski, R. Sadej (Lodz; Gdansk, Poland) (15')
145. Adjuvant, local radiotherapy effects on circulating immune response parameters in breast cancer patients. **N. Laytragoon Lewin**, T. Luetragoon, L. Shamoun, B.-Å. Andersson, D. Oliva, M. Strandeus, S. Löfgren, L.-E. Rutqvist, F. Lewin (Jönköping; Stockholm, Sweden; Phitsanulok, Thailand) (15')
316. Modeling and simulation approaches for the description of pharmacokinetics and pharmacodynamics of epacadostat. **S. Konstantinidou**, V. Karalis (Athens, Greece) (15')
309. Gene expression signature and immunohistochemical characterization of MDA-MB-231 triple negative breast cancer xenograft model exposed to proton radiations. **B. Tomasello**, F.P. Cammarata, V. Bravatà, L. Minafra, G.I. Forte, R. Tringali, G.A. Malfa, C. Di Giacomo, G.A.P. Cirrone, P. Pisciotta, G. Broggi, R. Caltabiano, R. Acquaviva, G. Russo (Catania; Cefalù, Italy) (15')
293. Laminin-511: PKM2, the linkage between cancer metabolism and DNA repair. **Y. Wang**, P. Shuai, Y. Liu, **S. Deng** (Chengdu, P.R. China) (10')

PHARMACOLOGY/TOXICOLOGY/ENVIRONMENT

Room C, 09:00-11:00

Saturday, October 12

Chair Persons: D. Kouretas, A.S. Veskoukis, V. Rapisarda

194. Personalized nutrition regimen and the redox biomarker issue: Five premises that should be followed. A.S. Veskoukis, **D. Kouretas** (Larissa, Greece) (30')
196. Evaluation of the effects of a highly rich in biophenols olive oil sample on blood and tissue redox status of rats. **P. Kouka**, A.S. Veskoukis, M. Halabalaki, A.-L. Skaltsounis, I. Taitzoglou, D. Kouretas (Larissa; Athens; Thessaloniki, Greece) (20')
199. Adipokines in shift workers. **V. Rapisarda**, S. Matera, E. Vitale, L. Rapisarda, D. Cinà, C. Ledda (Catania, Italy) (30')
197. Fertility and work-related stress in healthcare workers. **E. Cannizzaro**, C. Ledda, S. Matera, E. Vitale, A. Marconi, D. Cinà, V. Rapisarda (Palermo; Catania, Italy) (20')
198. Chronodisruption in healthcare workers. **C. Ledda**, L. Rapisarda, A. Savoca, E. Vitale, D. Cinà, V. Rapisarda (Catania, Italy) (20')

CLINICAL ONCOLOGY/SURGICAL ONCOLOGY

Room C, 11:30-13:20

Saturday, October 12

Chair Persons: N. Telang, E.T. Detorakis, D.P. Vageli

113. Stem cells from a model for genetically predisposed colon cancer. **N. Telang** (Montvale, NJ USA) (20')
147. Combined photoacoustic and fluorescence label-free microscopy for the *ex vivo* investigation of ocular melanotic lesions. G.J. Tserevelakis, K.G. Mavrikis, **E.T. Detorakis**, D. Pantazopoulou, E. Karamouzi, E. Lagoudaki, G. Zacharakis (Heraklion, Greece) (20')
153. Biliary tumorigenic effect on hypopharyngeal cells is significantly enhanced by pH reduction. **D.P. Vageli**, S.G. Doukas, C.T. Sasaki (New Haven, CT, USA) (20')
154. Temporal characteristics of NF- κ B inhibition in blocking bile-induced oncogenic molecular events in hypopharyngeal cells. **D.P. Vageli**, P.G. Doukas, S.G. Doukas, C.T. Sasaki (New Haven, CT, USA) (15')
190. Residential radon exposure and lung cancer risk in Kazakhstan. **R.I. Bersimbaev**, O.V. Bulgakova, A.A. Kusainova, A.Zh. Kausbekova, A.A. Aripova (Astana, Kazakhstan) (15')
326. The immune escape mechanism of malignant cells in bladder cancer. **A.H. Mohamed** (Cairo, Egypt) (10')
327. Ultrastructural study of neutrophil apoptotic changes in hepatitis C patients. **A.H. Mohamed** (Cairo, Egypt) (10')

MOLECULAR MEDICINE/PHARMACOLOGY

Room C, 15:30-17:00
Saturday, October 12

Chair Persons: W. Gottardi, T. Eckschlager, M. Nagl

163. Taurine and derivative clinical data. **A.M. Kyriakopoulos**, M. Nagl, W. Gottardi, S. Baliou, V. Zoumpourlis (Pireas; Athens, Greece; Innsbruck, Austria) (15')
225. Bromamine T, a new developable hygiene product. **W. Gottardi** (Innsbruck, Austria) (20')
235. Apoferritin as a vehicle for anticancer nanodrugs. T. Cerna, J. Hrabeta, Z. Heger, S. Dostalova, R. Indra, V. Adam, M. Stiborova, **T. Eckschlager** (Prague; Brno, Czech Republic) (20')
222. Perspectives of taurine derivatives. **M. Nagl** (Innsbruck, Austria) (20')
162. N-Bromotaurine and its stable analogue molecule (Bromamine T-BAT) exhibit a therapeutic effect against cancer and inflammation *in vitro* and *in vivo*. **S. Baliou**, M. Nagl, A.M. Kyriakopoulos, V. Zoumpourlis (Athens; Pireas, Greece; Innsbruck, Austria) (15')

MOLECULAR MEDICINE/MOLECULAR ONCOLOGY

Room C, 17:30-19:00
Saturday, October 12

Chair Persons: V. Zoumpourlis, E. Rizos

179. The possible low cancer risk in schizophrenic patients, through the regulatory role of microRNAs: Preliminary data. **E. Rizos**, N. Siafakas, E. Skourti, C. Papageorgiou, J. Tsoporis, Th. Parker, D.A. Spandidos, E. Katsantoni, K. Tsamakis, N. Nikolakakis, V. Zoumpourlis (Athens; Heraklion, Greece; Toronto, Canada) (20')
310. Role of p16 INK4a in uveal melanoma. **G. Ilardi**, R.M. Di Crescenzo, D. Russo, S. Varricchio, F. Merolla, F. Martino, A. Borzillo, S. Pignatiello, G. Borrelli, M.A. Vecchione, S. Staibano (Naples, Italy) (20')
314. PCAL and PCT monitoring in the study of anastomotic dehiscence. **F. Giambò**, E. Cucinotta (Messina, Italy) (15')
164. Cytoskeletal stressing modes in cancer cells. V. Gavriil, E. Sarantopoulou, Z. Kollia, M. Goulielmaki, V. Zoumpourlis, **A.C. Cefalas** (Athens, Greece) (15')
165. Existing immunotherapy approaches to prostate cancer treatment and novel combinations that circumvent therapeutic resistance. **M. Adamaki**, V. Zoumpourlis (Athens, Greece) (10')
166. Mesenchymal stem cells isolated from the umbilical cord act as potent anticancer agents. **M. Goulielmaki**, I. Christodoulou, V. Zoumpourlis (Athens, Greece) (10')

POSTERS (Poster viewing during the entire congress at Mystras Grand Palace Resort)

108. The complement cascade as a mediator of human malignant hematopoietic cell trafficking. **J. Ratajczak**, M.Z. Ratajczak (Louisville, KY, USA)
112. Comparative evaluation of the antitumor activity of tryptanthrin and its synthetic water soluble analog mostotrin. **A. Popov**, A. Klimovich, O. Styshova, T. Moskovkina, A. Schekotihin, N. Grammatikova, L. Dezhenkova, V. Stonik (Vladivostok; Moscow, Russia)
116. Colorectal carcinoma diagnosis in Slovakia: A challenge for family doctors. P. Makovicky, C. Podlupski, A. Juhasz, P. Makovicky, **L. Vannucci** (Komarno, Slovakia; Vestec; Prague, Czech Republic)
124. AID/APOBEC-mediated epigenetic changes in colorectal cancer. T. Christofi, **A. Zaravinos** (Nicosia, Cyprus)
125. The role of RNA editing in cancer development and prognosis. T. Christofi, **A. Zaravinos** (Nicosia, Cyprus)
148. Metformin induces caspase-independent apoptosis in human bladder carcinoma T24 cells. J.H. Jang, T.-J. Lee, E.-G. Sung, **J.-Y. Kim** (Daegu, Republic Korea)
151. Specific hydroxycinnamic acid derivatives synergize with the polyphenol carnosic acid against acute myeloid leukemia cells. **A. Trachtenberg**, K. Sidoryk, S. Muduli, S. Alreate, M. Cybulski, M. Danilenko (Beer Sheva, Israel; Warsaw, Poland)
170. A peptide nucleic acid targeting the *acpP* gene of *Pseudomonas aeruginosa* inhibits bacterial induced biological alterations in cystic fibrosis cells. E. D'Aversa, C. Tupini, E. Fabbri, M. Borgatti, I. Lampronti, A. Finotti, P.E. Nielsen, **R. Gambari** (Ferrara, Italy; Copenhagen, Denmark)
171. New synthetic isoxazole derivatives as potent inducer of fetal hemoglobin (HbF) in β -thalassemia. I. Lampronti, C. Zuccato, L.C. Cosenza, C. Tupini, C. Gemmo, R. Baruchello, D. Simoni, **R. Gambari** (Ferrara, Italy)
172. A PNA-based masking strategy for CFTR upregulation by targeting miR-145-5p binding sites of CFTR mRNA. S. Sultan, E. Fabbri, A. Tamanini, J. Gasparello, A. Manicardi, R. Corradini, A. Finotti, C. Tupini, I. Lampronti, M.C. Dechechi, G. Cabrini, **R. Gambari**, M. Borgatti (Ferrara; Verona; Parma, Italy)
173. Sirolimus-mediated induction of fetal hemoglobin in beta-thalassemia: Impact of the XmnI rs74482144 polymorphism. C. Zuccato, L.C. Cosenza, G. Breveglieri, C. Gemmo, I. Lampronti, E. Fabbri, N. Bianchi, M. Borgatti, J. Gasparello, A. Finotti, M. Prosdociimi, **R. Gambari** (Ferrara; Milano, Italy)
174. Non-invasive prenatal detection of beta-thalassemia mutations in maternal plasma using Droplet Digital PCR. E. D'Aversa, G. Breveglieri, P. Pellegatti, G. Guerra, **R. Gambari**, M. Borgatti (Ferrara, Italy)
176. Downregulation of LYAR is associated with induction of fetal hemoglobin in mithramycin-treated erythroid cells. L.C. Cosenza, J. Gasparello, M. Zurlo, C. Zuccato, R. Gambari, **A. Finotti** (Ferrara, Italy)
177. Upregulation of miR-34a-3p and miR-744-3p is associated with downregulation of PTEN in lymphoblastoid cells from Shwachman-Diamond Syndrome patients. J. Gasparello, C. Papi, G. Breveglieri, C. Tupini, E. D'Aversa, V. Bezzerri, M. Cipolli, R. Gambari, M. Borgatti, **A. Finotti** (Ferrara; Ancona, Italy)
178. Analysis of the miRNome as a possible tool for the detection of autologous blood transfusion misuse in sport. J. Gasparello, N. Lamberti, C. Papi, E. Fabbri, L.C. Cosenza, I. Lampronti, F. Manfredini, R. Gambari, **A. Finotti** (Ferrara, Italy)
180. Monoclonal antibodies to human norovirus that was growing in cell culture. **V. Sologub**, I. Koromyslova (Moscow, Russia)
181. HLA polymorphism in Transylvanian population in comparison with other populations. **M.L. Vică**, G.Z. Nicula, C.I. Bondor, C.V. Siserman, H.V. Matei (Cluj-Napoca, Romania)
184. Polyoxometalates' antitumor activity tested on HeLa cancer cell line. **G. Nicula**, O. Sorițău, D. Rusu, M. Filip, M. Vică, R. Ungur, H. Matei, C. Siserman, Ș. Bălici (Cluj-Napoca, Romania)
192. Feed supplemented with wine by-products enhances the antioxidant defense system of broiler tissues. **S. Makri**,

A.S. Veskoukis, D. Kouretas (Larisa, Greece)

193. Effects of developmental stages and sex on the redox status of farm animals. **Z. Skaperda**, A.S. Veskoukis, A. Argyriadou, G. Arsenos, D. Kouretas (Larissa, Greece)
195. Assessment of antioxidant activity of extracts from *Conium divaricatum*, *Ruta graveolens* and *Artemisia arborescens*. D. Ladas, E. Kontozisi, C.A. Kamvoukou, P. Kouka, E. Kerasioti, F. Tekos, D. Kouretas, S. Haroutounian, **D. Stagos** (Larissa; Athens, Greece)
206. Updating taxonomy changes: RSV is now known as Orthopneumovirus. **I.N. Mammas**, D.A. Spandidos (Heraklion, Greece)
207. Predicting asthma following RSV-positive bronchiolitis in early childhood. **C. Koutsaftiki** (Penteli, Greece)
208. Thrombocytosis and RSV infection in hospitalised children with bronchiolitis. **I.N. Mammas**, D.A. Spandidos (Heraklion, Greece)
209. Heliox and RSV-positive bronchiolitis. **A. Papatheodoropoulou** (Athens, Greece)
210. MicroRNAs as potential bio-markers in children with RSV infection. **C. Koutsaftiki** (Penteli, Greece)
211. RSV infection: Not for children only. **E. Kozanidou**, V. Achtsidis (Piraeus, Greece)
212. RSV and precision medicine: Time for a more precise approach to diagnosis, treatment and prevention. **M. Theodoridou** (Athens, Greece)
227. Pine bark extract in oncology. **P. Slodnik**, C. Zeller (Ruti, Switzerland)
229. A multi-layered systems approach for renal cell carcinoma. L. Cooley, W. Souleyreau, J. Rudewicz, M. Nikolski, K. Clarke, F. Falciani, E. Ribot, S. Benzekry, C. Tang, M. Dufies, D. Lambrechts, G. Pages, **A. Bikfalvi** (Pessac; Nice, France; Liverpool, UK; Leuven, Belgium)
230. Anti-endoglin (CD105) monoclonal antibodies: Tools for cancer research and treatment. **I. Smirnov**, I. Gryazeva, A. Stolbovaya, A. Pinevich, O. Shashkova, M. Samoylovich (Saint-Petersburg, Russia)
250. A new scaffold for selective inhibition of human monoamine oxidase B. **M.L. Di Paolo**, M.S. Christodoulou, A.M. Calogero, L. Pinzi, G. Rastelli, D. Passarella, G. Cappelletti, L. Dalla Via (Padova; Milano; Modena, Italy)
251. RSV bronchiolitis and paediatric asthma. **P. Korovessi** (Penteli, Greece)
252. Post infectious bronchiolitis obliterans caused by respiratory syncytial virus (RSV) in children. G. Grivas, C. Lymperatou, **P. Korovessi** (Penteli, Greece)
253. Overlap between RSV, influenza viruses and human metapneumovirus in childhood. **I.N. Mammas**, D.A. Spandidos (Heraklion, Greece)
258. Thymoquinone and Difluoromethylornithine synergistically induce apoptosis of lymphoblastic leukemia cells through the modulation of epigenetic pathways. **R.A. Sheikh**, S.S. Razvi, J.A. Khan, M.A. Zamzami, H. Choudhry, M. Alhosin (Jeddah, Saudi Arabia)
261. Expression of beta-defensins 1 and 2 in total saliva of individuals with a 35-day experimental gingivitis model. **S.K. Ramírez-Thomé**, R. Díaz-Castillejos, M.C. Franco-Arellanes, V. Jiménez-Castillo, Y. Ruíz-Pichardo, A.P. Vargas-Casillas, **C.J. Solórzano-Mata** (Oaxaca; Mexico city, Mexico)
266. Next-generation sequencing for the identification of molecular markers in diverse childhood malignancies. **S. Heinsohn**, K. Lehmborg, U. zur Stadt (Hamburg, Germany)
268. Effect of glioblastoma radiotherapy on the extracellular matrix of normal mouse brain tissue in an experimental system *in vivo*. M.O. Politko, A.I. Prokaeva, O.A. Pashkovskaya, A.A. Zheravin, G.M. Kazanskaya, A.V. Volkov, **M.A. Kolpakova**, A.Y. Tsidulko, A.V. Suhovskih, S.V. Aidagulova, E.V. Grigorieva (Novosibirsk, Russia)
286. Molecular analysis causing depressive-like behaviors in interleukin-18-deficient mice: Gene expression profiles in the

brain. **T. Ikawa**, K. Yamanishi, K. Mukai, T. Hashimoto, M. Miyauchi, K. Ikubo, N. Uwa, Y. Watanabe, C. Yamanishi, H. Okamura, H. Matsunaga (Hirakata; Nishinomiya, Japan) (10')

294. EGF in exhaled breath condensate as diagnostic method for non-small cell lung cancer. **J.-L. Chen**, S.-M. Yao, X.-D. Lv, Q.-C. Yang, J.-R. Chen (Nantong, P.R. China)
295. Study of the epigenetic mechanisms through which miR-155 promotes the cellular growth of liver cancer. **X. Xin**, D. Lu (Shanghai, P.R. China)
296. Study of the molecular mechanisms through which pyruvate kinase M2 (PKM2) regulates the cellular proliferation of liver cancer. **Y. Lu**, D. Lu (Shanghai, P.R. China)
297. Normalisation of serum vitamin D levels improves glycemic parameters in patients with type two diabetes mellitus. **M.A. Alfaqih**, A. Araidah (Irbid, Jordan)
298. Systematic analyses of a novel microRNA-associated signature as the diagnosis biomarker for esophageal squamous cell carcinoma. **C.-Y. Li**, W.-W. Zhang, J.-L. Xiang, X.-H. Wang, J.-L. Wang, J. Li (Lanzhou; Wuwei, P.R. China)
299. Metformin reduces the expression of cytokines and chemokines in rat intestinal smooth muscle cells. **A. Al-Dwairi** (Irbid, Jordan)
300. Antitumor activity of cannabidiol (CBD) and snail/rapana extracts on a variety of human malignant cells. A. Trochopoulos, E. Ivanov, L. Velkova, A. Dolashki, P. Dolashka, **S.M. Konstantinov** (Sofia, Bulgaria)
301. Intratumoral subpopulation of cancer stem cells as predictive marker in cervical squamous cell carcinoma patients receiving chemoradiotherapy. **E.I. Selivanova**, I.A. Zamulaeva, L.S. Mkrtchyan, O.N. Matchuk, G.Z. Kulieva, L.I. Krikunova (Obninsk, Russia)
302. New curcumin nanoformulation and its *in vitro* effect on cutaneous T-cell lymphoma cells. **A. Trochopoulos**, M.M. Zaharieva, K. Yoncheva, I. Pencheva-El Tibi, S.M. Konstantinov, M. Berger (Sofia, Bulgaria; Heidelberg, Germany)
306. Changes in *O*-GlcNAcylation modifies the production of superoxide anion in macrophages. **C. Díaz-Hernández**, D. Illescas-Barbosa, V. Jiménez-Castillo, J.A. Castellanos-Martínez, B.X. Ávila-Curiel, B. Fernández-Rojas, P.A. Hernández-Cruz, A. Torres-Rivera, C.J. Solórzano-Mata (Oaxaca; México city, Mexico)
319. A phenolic acid, gallic acid, inhibited the progression and migration of prostate cancer by decreasing histone deacetylase 1 and 2 expressions. Y.-G. Jang, J.-H. Kang, **K.-C. Choi** (Cheongju, Republic of Korea)
320. Therapeutic gene delivery of cytosine deaminase and interferon-beta via engineering stem cells resulted in the inhibition of progression of renal cell carcinoma. G.-S. Kim, S.-M. Lee, **K.-C. Choi** (Cheongju, Republic of Korea)
321. Myocardial differentiation appeared to be hindered by cigarette smoke components in mouse embryonic stem cells. C.-W. Kim, **K.-C. Choi** (Cheongju, Republic of Korea)
322. Silent male breast cancer: The natural reservoir of the disease in autopsy specimens. **Z. Sidiropoulou**, A.P. Vasconcelos, C. Couceiro, C. Dos Santos, A. Araujo, I. Alegre, C. Santos, F. Costa, R. Sampaio, V. Fonseca, C. Neves, F. Cardoso, P. Gascon (Lisbon, Portugal; Barcelona, Spain)

